Credit Suisse

Credit Suisse is the bank at the center of the Nightingale-account mystery: a London account sends money that pays for Holly Walsh’s experimental Ditrimantelline treatment, while the identity and status of its holder remain undisclosed. The bank’s limited presence in the story is consequential precisely because a practical lifeline for Holly is also a possible clue to hidden corporate funds and Jane Glasson’s disappearance.

The Nightingale Account

Holly tells Don Challenor and Blake that the money comes from Credit Suisse in London, where the account is held in the name of Nightingale. When asked whether Nightingale is a personal or company name, the bank will not say. The name thus identifies the source of payments without establishing who controls them or what kind of entity stands behind them.

The account supports Holly’s access to Ditrimantelline, an experimental medicine she says she could not afford herself. In her online blogs, she describes the treatment as bringing her symptoms under control and giving her life back; Anna Marchant also says it has been transformative. The bank account is therefore not merely an abstract financial lead: its continuing payments are tied to a treatment Holly relies on.

Anonymity and the Benefactor

Holly says that her first contact came by email from someone using the name Luscinia, Latin for nightingale. The sender claimed to work in pharmaceuticals, objected to the high cost of effective drugs, and offered to supply Ditrimantelline anonymously to avoid getting into trouble. The account name echoes that assumed identity, but the evidence does not establish that Luscinia owns or operates the account.

The anonymity has both a protective and a troubling dimension. It allows Holly to receive costly medication without knowing who is paying, but it also leaves her unable to judge whether the arrangement depends on an employee diverting company money. Holly worries that Luscinia may work for Harkness Pharmaceuticals and that the payments could stop if the diversion is uncovered. She understands the source as uncertain even while describing the treatment’s concrete benefit.

The Account as an Investigative Lead

Holly recounts that a private investigator working for creditors of Jack Harkness had recently questioned her about the Credit Suisse payments. He knew she was receiving money from the Nightingale account and asked why; she explained that it paid for her medication. Holly says he did not mention Jane Glasson and, as far as she could tell, was not initially interested in Jane’s disappearance.

She nevertheless suspects the investigator may know Luscinia’s identity. She asks Don and Blake to persuade him to disclose enough to show that the benefactor is not Jane, which would help Don in his inquiry for Andrew Glasson. The bank’s refusal to identify the account holder leaves the investigators dependent on other people and other records for an answer; Credit Suisse is presented as a point of financial connection, not as the source of an explanation.

Scale and Significance

The account is distinguished from the much larger sums alleged to have been diverted from Quintagler Industries. Investigators say those funds were routed over several years through subsidiaries of shell companies ultimately owned by Harkness, while the London Nightingale account is described as a one-off and comparatively small. Its modest scale does not make it irrelevant: it is a traceable channel that may connect the pharmaceutical company’s finances to an anonymous benefactor and a patient’s treatment.

Credit Suisse consequently occupies a narrow but pivotal place in the novel’s financial investigation. The bank’s location and account name are known; whether the account is personal or corporate, who controls it, and whether its funds are linked to Harkness Pharmaceuticals remain unresolved in the evidence presented. That gap between a visible payment and an invisible payer makes the account both a source of support for Holly and a test of how far the investigators can follow money without access to the identity behind it.